Download CRIMSON brochure

Treatment, Decision Making and Relapsing Remitting Multiple Sclerosis

The CRIMSON Project Decision Aid

This website aims to help people with Relapsing Remitting Multiple Sclerosis (RRMS) make decisions about starting, switching or stopping taking Disease Modifying Treatment (DMTs) medicines. It has information and prompts to help people with RRMS, and their friends and family, talk with health professionals about why some treatments fit into their life better than others.

The three types of RRMS management decisions this website helps people think about are:

  1. Deciding between Relapse Management or start taking a DMT
  2. Deciding between DMT options
  3. Deciding to switch or stop DMT options

Living with RRMS means making many decisions about different treatments as your life changes. The facts and guidance in this booklet are to help you think about what is important to you when planning your treatments, and when talking with others. [15, 27-33].

People use the website in different ways by clicking on terms in the decision map on the right or the section tabs above. The website is split into the following sections:

While using the decision aid you may view your notes at any point using the "view my notes" button in the bottom right hand corner of the screen. From the notes page you will have the option to print or save your notes.

Navigation Map

Start using the CRIMSON Project Decision Aid

Go to Section A


This website was made by the Considering Risks and Benefits in Multiple Sclerosis Treatment Selection (CRIMSON) project team. Every effort was made to provide accurate information at the date of publication (March 2021). NOTE: facts about treating RRMS in the UK change over time. To check facts about RRMS and which treatment works best for you, talk about your decision making and choices with your MS professionals.

COVID-19: Ask your MS Teams about how COVID-19 affects your care and treatment decisions.

Visit the project team page to find more about the study and the team.